313 related articles for article (PubMed ID: 25043459)
1. Comparative effects of teriparatide, denosumab, and combination therapy on peripheral compartmental bone density, microarchitecture, and estimated strength: the DATA-HRpQCT Study.
Tsai JN; Uihlein AV; Burnett-Bowie SA; Neer RM; Zhu Y; Derrico N; Lee H; Bouxsein ML; Leder BZ
J Bone Miner Res; 2015 Jan; 30(1):39-45. PubMed ID: 25043459
[TBL] [Abstract][Full Text] [Related]
2. Effects of Two Years of Teriparatide, Denosumab, or Both on Bone Microarchitecture and Strength (DATA-HRpQCT study).
Tsai JN; Uihlein AV; Burnett-Bowie SM; Neer RM; Derrico NP; Lee H; Bouxsein ML; Leder BZ
J Clin Endocrinol Metab; 2016 May; 101(5):2023-30. PubMed ID: 26964731
[TBL] [Abstract][Full Text] [Related]
3. Teriparatide Followed by Denosumab in Premenopausal Idiopathic Osteoporosis: Bone Microstructure and Strength by HR-pQCT.
Agarwal S; Shiau S; Kamanda-Kosseh M; Bucovsky M; Kil N; Lappe JM; Stubby J; Recker RR; Guo XE; Shane E; Cohen A
J Bone Miner Res; 2023 Jan; 38(1):35-47. PubMed ID: 36335582
[TBL] [Abstract][Full Text] [Related]
4. Effects of Combination Denosumab and High-Dose Teriparatide Administration on Bone Microarchitecture and Estimated Strength: The DATA-HD HR-pQCT Study.
Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Leder BZ; Tsai JN
J Bone Miner Res; 2021 Jan; 36(1):41-51. PubMed ID: 32790196
[TBL] [Abstract][Full Text] [Related]
5. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study.
Tsai JN; Nishiyama KK; Lin D; Yuan A; Lee H; Bouxsein ML; Leder BZ
J Bone Miner Res; 2017 Oct; 32(10):2001-2009. PubMed ID: 28608571
[TBL] [Abstract][Full Text] [Related]
6. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
7. Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis.
Macdonald HM; Nishiyama KK; Hanley DA; Boyd SK
Osteoporos Int; 2011 Jan; 22(1):357-62. PubMed ID: 20458576
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide increases strength of the peripheral skeleton in premenopausal women with idiopathic osteoporosis: a pilot HR-pQCT study.
Nishiyama KK; Cohen A; Young P; Wang J; Lappe JM; Guo XE; Dempster DW; Recker RR; Shane E
J Clin Endocrinol Metab; 2014 Jul; 99(7):2418-25. PubMed ID: 24684466
[TBL] [Abstract][Full Text] [Related]
9. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
10. The Effect of Zoledronic Acid on Bone Microarchitecture and Strength after Denosumab and Teriparatide Administration: DATA-HD Study Extension.
Ramchand SK; David NL; Lee H; Bruce M; Bouxsein ML; Tsai JN; Leder BZ
J Bone Miner Res; 2023 Jan; 38(1):26-34. PubMed ID: 36333954
[TBL] [Abstract][Full Text] [Related]
11. Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients.
Bonani M; Meyer U; Frey D; Graf N; Bischoff-Ferrari HA; Wüthrich RP
Kidney Blood Press Res; 2016; 41(5):614-622. PubMed ID: 27622692
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study.
Chiba K; Okazaki N; Kurogi A; Watanabe T; Mori A; Suzuki N; Adachi K; Era M; Yokota K; Inoue T; Yabe Y; Furukawa K; Kondo C; Tsuda K; Ota S; Isobe Y; Miyazaki S; Morimoto S; Sato S; Nakashima S; Tashiro S; Yonekura A; Tomita M; Osaki M
Bone; 2022 Jul; 160():116416. PubMed ID: 35398293
[TBL] [Abstract][Full Text] [Related]
13. Hip and spine strength effects of adding versus switching to teriparatide in postmenopausal women with osteoporosis treated with prior alendronate or raloxifene.
Cosman F; Keaveny TM; Kopperdahl D; Wermers RA; Wan X; Krohn KD; Krege JH
J Bone Miner Res; 2013 Jun; 28(6):1328-36. PubMed ID: 23281041
[TBL] [Abstract][Full Text] [Related]
14. Spine Volumetric BMD and Strength in Premenopausal Idiopathic Osteoporosis: Effect of Teriparatide Followed by Denosumab.
Agarwal S; Shane E; Lang T; Shiau S; Kamanda-Kosseh M; Bucovsky M; Lappe JM; Stubby J; Recker RR; Hu Y; Wang Z; Edward Guo X; Cohen A
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2690-e2701. PubMed ID: 35428889
[TBL] [Abstract][Full Text] [Related]
15. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Tsai JN; Uihlein AV; Lee H; Kumbhani R; Siwila-Sackman E; McKay EA; Burnett-Bowie SA; Neer RM; Leder BZ
Lancet; 2013 Jul; 382(9886):50-6. PubMed ID: 23683600
[TBL] [Abstract][Full Text] [Related]
16. Teriparatide treatment exerts differential effects on the central and peripheral skeleton: results from the MOAT study.
Paggiosi MA; Yang L; Blackwell D; Walsh JS; McCloskey E; Peel N; Eastell R
Osteoporos Int; 2018 Jun; 29(6):1367-1378. PubMed ID: 29520607
[TBL] [Abstract][Full Text] [Related]
17. A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: Relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover.
Burghardt AJ; Kazakia GJ; Sode M; de Papp AE; Link TM; Majumdar S
J Bone Miner Res; 2010 Dec; 25(12):2558-71. PubMed ID: 20564242
[TBL] [Abstract][Full Text] [Related]
18. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
[TBL] [Abstract][Full Text] [Related]
19. Bone Mineral Density Response With Denosumab in Combination With Standard or High-Dose Teriparatide: The DATA-HD RCT.
Ramchand SK; David NL; Leder BZ; Tsai JN
J Clin Endocrinol Metab; 2020 Mar; 105(3):890-7. PubMed ID: 31674641
[TBL] [Abstract][Full Text] [Related]
20. Effects of Teriparatide, Denosumab, or Both on Spine Trabecular Microarchitecture in DATA-Switch: a Randomized Controlled Trial.
Tsai JN; Jiang LA; Lee H; Hans D; Leder BZ
J Clin Densitom; 2017; 20(4):507-512. PubMed ID: 28624340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
